10 mg Prasugrel Tablet Blister.jpg (10 mg Prasugrel Tablet Blister)
Prasugrel Tablet, Film Coated
Product Images NDC 60687-883
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Prasugrel (NDC 60687-883). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
10 mg Prasugrel Tablets Carton.jpg (10 mg Prasugrel Tablets Carton)
This text contains information about Prasugrel tablets in two different quantities - 20 tablets and 30 tablets. It provides details about the active ingredient, dosage, storage instructions, and the manufacturer. The tablets contain Prasugrel hydrochloride USP equivalent to 10 mg of Prasugrel. It recommends checking the full prescribing information for the usual dosage. The tablets are distributed by American Health Packaging and are to be stored at a temperature range of 20°C to 25°C. The text also mentions not to use the product if the blister is torn or broken.*
Ahp88321
Figure 1: Non-cabg-related Timi Major Or Minor Bleeding Events. (Prasugrel Fig1)
Figure 2: Inhibition (mean±sd) Of 20 μm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Prasugrel 60 mg. (Prasugrel Fig2)
This text provides information on Platelet Aggregation over time, showing mean and standard deviation values for 20 uM ADP concentration. The graph likely plots the inhibition percentage over a 24-hour period.*
Figure 3: Time To First Event Of Cv Death, Mi, Or Stroke (triton-timi 38). (Prasugrel Fig3)
Figure 4: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Ua/nstemi Patients. (Prasugrel Fig4)
This text appears to present baseline characteristics of participants in a study comparing the medications Prasugrel and Clopidogrel. The characteristics include factors such as age, gender, body weight, region, diabetes mellitus, previous medical history (MI, PCI, CABG, TIA/stroke), and time from symptom onset. The data also includes the use of metabolic syndrome, stent type, and the use of GP IIb/IIIa inhibitor. The text also mentions that Prasugrel may be better than Clopidogrel based on the hazard ratio provided.*
Figure5 (Prasugrel Fig5)
This is a statistical comparison between the characteristics and outcomes of patients treated with Prasugrel versus Clopidogrel for overall STEMI. Data includes baseline characteristics such as age, gender, body weight, region, diabetes, metabolic syndrome, previous medical history, time from symptom onset, stent type, and GP inhibitor use. The comparison also indicates that Prasugrel may be better than Clopidogrel based on the hazard ratio.*
Chemical Structure (Prasugrel Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
